LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against CTI BioPharma Corp. (“CTI” or the “Company”) (Nasdaq: CTIC). Investors who purchased or otherwise acquired shares between March 4, 2014 and February 9, 2016, (the “Class Period”), are encouraged to contact the firm no later than 60 days from the date of this notice.
If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 708, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the complaint, the Company failed to disclose that: (1) CTI’s clinical trials showed that patient deaths were related to pacritinib usage; (2) CTI’s application for the approval of pacritinib would likely be withdrawn; (3) the Company’s future revenues were impaired; and (4) that the company lacked adequate internal controls.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.